New Proposal of Therapeutic Drug for Depression in Parkinson?s Disease
Author(s): Lourdes de Fatima Ibanez Valdes1, Humberto Foyaca Sibat2*
Abstract
Objectives: The main aim of this study is to discuss the latest information released into the medical literature regarding novel drug therapy of depression in Parkinson’s disease.
Methods: A wide search of the medical literature of the following databases, PubMed/MEDLINE, Scopus, and Embase, was performed to find articles related to novel information on the pathogenesis of depression in PD. From 01 January 2000 to 31 January 2026, we searched the medical literature following PRISMA guidelines. We searched Scopus, Embase, and PubMed Central using: “Pathogenesis of depression,” “pathogenesis of Parkinson’s disease,” “novel treatment for depression,” “gut-brain axis therapy,” “dysbiosis,” “limbic system,” “major depressive disorders,” “habenula dysfunction,” “ibogaine” and “treatment of mood disorders”.
Results: A literature search initially yielded 1563 articles. After removing 911 duplicates based on title and abstract review, 652 publications remained. Of these, 478 did not meet the inclusion/exclusion criteria, leaving 174 studies that investigated the pathogenesis of depression in PD. Among these, five manuscripts presented novel information on the treatment of depression in PD. However, quality assessment revealed that none of the selected articles delivered new hypotheses.